focus -WSS

focus

author：focus 2025-10-02 00:27:46 - browse：22

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Search called off for baby washed away in Pennsylvania flash flood

hotspot

WSS

New lawsuit accuses health insurer Cigna of denying claims in bulk

Bispecific antibodies are next new thing in cancer immunotherapy

Patients, doctors are clashing about side effects of hormonal birth control

Eli Lilly’s Mounjaro succeeds in second weight

Timeline: Key moments in fight for gay rights

Altering the blood type of lungs raises potential for universal organs for transplants

hotspot

focus

knowledge

United colonoscopy coverage change 'may cost lives,' doctors say

Can medical device makers keep up in the race to treat obesity?

Virginia high school admissions case could be legal follow

New lawsuit accuses health insurer Cigna of denying claims in bulk

Supreme Court strikes down use of affirmative action

Can medical device makers keep up in the race to treat obesity?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Senate panel puts off hardest PBM reforms for another day

Medicare details structure of new drug price negotiation program

Timeline: Key moments in fight for gay rights

focus

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

A public health expert passes on football's full body collisions for youths

The thinking behind the controversial eating disorder chatbot Tessa

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

New Alzheimer's drugs heat up race for early detection blood tests

leisure time

hotspot

leisure time

hotspot